Anavex Life Sciences Corp. (AVXL) Presents Positive Initial Data for Parkinson’s Disease Drug Candidate
At the World Parkinson Congress 2016 in Portland earlier today, Anavex Life Sciences (NASDAQ: AVXL) presented preclinical data in a poster titled “Investigating the potential neurorestorative effects of a clinical Sigma-1 receptor agonist in a mouse model of Parkinson’s disease.” Initial data demonstrated that the company’s ANAVEX 2-73, a sigma-1 receptor agonist, restores function in a classic animal model of Parkinson’s disease. The company reports “significant” improvements across the board, including behavioral, histopathological, and neuroinflammatory endpoints. “This initial data is encouraging, and together with already available clinical safety and tolerability data on ANAVEX 2-73, might accelerate the exploration of ANAVEX…







